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ABSTRACT:  Despite promising preclinical data, few novel stroke therapies have shown 
efficacy in man.  Efforts to improve standards in conduct and reporting of preclinical research 
are ongoing.  In clinical trials, inconsistency in outcome measures led to regulatory agencies 
and funders mandating use of a core set of functional outcomes.  Our aim was to describe 
functional outcome measures in preclinical stroke and vascular cognitive impairment (VCI) 
studies.  From 14 high impact journals (January 2005-December 2015 inclusive), 91,956 papers 
were screened with 1,302 full texts analyzed for stroke (ischemic and haemorrhagic) and 56 for 
VCI studies.  In total 636 (49%) stroke and 37 (66%) VCI papers reported functional outcome 
measures.  There were 74 different functional assessments reported in stroke and 20 in VCI 
studies.  Neurological deficit scores (74%) and Morris Water Maze (60%) were most commonly 
used in stroke and VCI, respectively.  However, inconsistencies in methods used to assess and 
score recovery were noted.  Neurological and behavioural functional outcome measures are 
increasingly used in preclinical stroke or VCI studies, however, there is substantial variation in 
methods.  A strict standardized outcome set may not be suitable for translational work, but 
greater consistency in choice, application and reporting of outcomes may improve the science. 
 
KEY WORDS: Rodent, MCAO, haemorrhagic stroke, functional outcome measure, vascular 
cognitive impairment.  
INTRODUCTION 
The traditional translational pathway, where compounds are first trialed in animals and then 
humans, has provided limited success in stroke and vascular cognitive impairment (VCI).  Many 
compounds show promise in early phase trials but fail to deliver benefit when tested in patients 
with cerebrovascular disease1.  Following a number of neutral studies of putative 
neuroprotectants2, the stroke research community, pharmaceutical industry and regulatory 
agencies suggested methods to improve the translational pathway.  Resulting guidance 
documents, from STAIR (Stroke Therapy Academic Industry Roundtable)3, 4 and others5, 6 were 
designed to raise standards in both preclinical and clinical stroke research.  To prove the 
efficacy of any new treatment a robust measure of effect is required.  In a disabling condition 
such as stroke, measures of function are important metrics of assessment.  Functional 
measures are now recommended as the primary outcome in acute stroke interventional trials 
and certain regulatory agencies and funders mandate their collection in stroke studies.  Similar 
efforts towards a consensus approach for clinical VCI research have recently been proposed7. 
 
Systematic reviews of assessments applied in contemporary clinical trials have described 
substantial heterogeneity in choice and application of functional outcome measures in both 
stroke and VCI studies8, 9.  Even in more niche areas, such as assessment of post-stroke 
cognitive and mood disorders, there are almost as many outcome measures employed as there 
are studies10.  This variation in assessment is inefficient as it precludes meaningful comparative 
analyses of studies and complicates any attempt to pool data across studies.  In recognition of 
this, consensus statements on the preferred functional outcomes for use in stroke and dementia 
clinical studies have been created11, 12.  
 
There are numerous functional outcome assessments available for preclinical ischemic stroke 
and VCI studies, especially rodent models13, and with choice comes the potential for 
inconsistency in assessment.  Classically in preclinical stroke research, one measures 
sensorimotor impairment.  Motor problems are common following stroke in man but additional 
impairments are also observed and an exclusive motor focus may be overly reductionist.  In VCI 
models, assessments often rely on memory impairment, although novel assessments that 
capture other cognitive domains more aligned with the clinical VCI phenotype have been 
described14.  Arguments for the importance of using functional outcome measures in humans 
may also be true for animal studies.  As in human cerebrovascular research, there are many 
potential functional assessment paradigms for different animal models.   
 
The aim of this study was to characterize preclinical stroke (ischemic and haemorrhagic) and 
VCI trials from the last 11 years, looking at 14 highly cited, exemplar journals from the fields of 
cerebrovascular science.  Our objectives were to describe the frequency of use, methodology 
applied for functional (sensorimotor, behavioural and neurocognitive) outcome measures as 
well as temporal trends.  To put these results in context, we also described preference of 
species, sex and disease models employed. 
 
 
METHODS 
Study Design. Best practice guidance in systematic review (Preferred Reporting Items for 
Systematic Review and Meta-Analysis [PRISMA]) was followed, where appropriate.  As the aim 
was to describe the use of outcomes, no assessments of the quality of the included trials’ 
design, methods or conclusions were made.  A pre-specified protocol (researchregistry1509) 
was followed.  Our approach was based on a previous review of functional assessments in 
clinical stroke trials8, 10. 
 
Paper screening. Following initial scoping of the literature, the search was limited to 14 journals, 
representing a broad field of translational cerebrovascular research.  Choice of titles was made 
by the author team.  Based on impact factor, reputation within the field and frequency of 
publication of relevant stroke and/or VCI studies the senior authors suggested a list of potential 
titles that could represent the following themes: clinical stroke (three titles chosen in this area); 
pre-clinical stroke; experimental neurology; neuroscience; neurorehabilitation and vascular 
science.  Through discussion a consensus was reached as to the top two titles for each 
category.  The primary criterion for selection was visibility within the international research 
community (Supplementary Table I).  They were: Brain (Oxford University Press); Circulation 
(American Heart Association, AHA); Experimental Neurology (Elsevier); Hypertension (AHA), 
International Journal of Stroke (World Stroke Organization, Sage Publishers); Journal of 
Cerebral Blood Flow and Metabolism (International Society of Cerebral Blood Flow and 
Metabolism, Sage Publishers); Journal of Neuropathology and Experimental Neurology 
(American Association of Neuropathologists, Oxford University Press); Journal of Neuroscience 
(Society for Neuroscience); Journal of Stroke and Cerebrovascular Disease (National Stroke 
Association, Elsevier); Nature Neuroscience (Nature Publishing Group); Neurobiology of 
Disease (Elsevier); Neurorehabilitation and Neural Repair (Sage Publishers); Stroke (AHA); 
Translational Stroke Research (Springer). 
 
Inclusion and Exclusion criteria. The search was limited to original papers published January 
2005 - December 2015 inclusive to capture papers before and after quality guidelines such as 
STAIR3, 4.  Four independent researchers (T.M.H., C.O., Z.P., L.F.) hand searched the chosen 
publications and screened titles/abstracts.  Inclusion criteria were: original research, published 
in one of the chosen journals, use of animal stroke or VCI model.  To ensure no potential 
manuscripts were missed, all journal content was reviewed, including letters, editorials and 
short reports.  Additional methodology described in online or paper supplements was assessed, 
where available.  As the focus was around the content of published papers, where aspects of 
methodology were unclear, authors of the papers were not contacted.  When looking for the 
original citation describing a model that was not described in the index publication, if more than 
three further citations were cross-checked and lacked original scaling, these methods were 
considered as not found.  Where more than one paper described the same dataset, only the 
primary publication was included, unless other publications reported differing outcome 
measures.   
 
The aim of the study was to collate stroke and VCI animal trials with functional outcome 
measures, where ‘functional outcome’ was defined as a quantified measure across any of the 
WHO-ICF domains of impairment, activity (disability) or participation (handicap).  A functional 
measure was accepted, where it was used as either the primary or secondary end-point of the 
study.  For the purposes of this review, ‘trial’ was defined as any research describing the effects 
of an active intervention.  WHO criteria for stroke was used to define the scope and within the 
stroke rubric, models of both ischemic and hemorrhagic stroke were included.  VCI studies were 
defined as studies, where vascular interventions were used to emulate one (or more) of the 
neuropathological changes associated with VCI and where the purpose of the model was to 
create dementia or a cognitive impairment phenotype.  
 
Data Extraction From eligible papers, relevant data were extracted onto a standardized, piloted, 
proforma spreadsheet.  Items of interest were: journal title, year of publication, animal model 
(sex, species ± genus), stroke model, VCI model, functional outcome measure(s) (primary and 
secondary).  The name of the functional outcome assessment used was taken directly from the 
text of the paper.  If the assessment was not named or described in the text, accompanying 
citations were referred to.  Where an assessment was described as “modified”, content was 
compared to the primary scale.  If fundamental aspects of measurement differed, the measure 
was included as a distinct outcome.  A test was counted as a single score if it was a battery or 
composite or various assessments that were combined as a single result (e.g. neuroscore). 
 
Functional assessments were categorized as either neurological scales (closest to impairment 
measures using WHO-ICF terminology) and functional tasks (closest to activity measures using 
WHO-ICF).  Temporal trends in the use of functional outcomes were described.  
 
Statistical Analysis.  Workflow was described with a PRISMA style flow diagram.  Frequency 
was described as functional outcomes with the use of basic statistics, non-parametric or 
proportional, as required.  Each category was described as number of papers as well as 
proportion.  Results were reported as the top ten measures.  Interquartile range (IQR) was 
calculated to show data dispersion.  Numbers of papers were compared with an unpaired t-test 
comparing articles grouped into two groups; published 2005-2010 and papers published 2011-
2015, inclusive with 2010 chosen as a time-point when core outcomes and guidance in 
reporting of outcomes become the standard in clinical stroke research   All analyses were 
performed using Prism for Windows (4.00, Graphpad) software and p<0.05 was considered 
significant. 
  
RESULTS  
Frequency of functional measures and temporal trends  
Of 91,956 papers screened, 23,802 had a stroke focus and 317 VCI.  Primary screening 
revealed 2165 and 229, respectively as potentially relevant and of these, 863 (40%) and 88 
(38%), respectively, did not meet the inclusion criteria.  For stroke, full text review was 
conducted on 1,302 papers with 636 (49%) used for final analysis.  The majority of exclusions 
(666, 51%) were due to no reporting of a functional measure.  For VCI, 56 papers were 
assessed in full, 19 (34%) exclusions reported no functional outcome measures and 37 (66%) 
papers were included in the final analysis (Figure 1). 
 
The number of stroke (Figure 2A) and VCI (Figure 2B) related papers reporting functional 
outcome measures increased over the 11 years studied.  A significant increase in stroke papers 
describing functional outcome assessments was observed after 2010, from a median of 32.5 
(range:30-38; IQR:7) papers annually before 2010 to a median of 82 (range:75-101; IQR:19.5) 
papers annually since 2011 (t-test; P<0.0001). 
 
Animal species, sex and model preferences 
Rodent models were most commonly used in both stroke and VCI studies (Figure 3A).  In stroke 
papers, there was variation in the animal models employed, with 622 (98%) of the papers using 
rodent models (339 rat, 282 mice, 1 gerbil) and 18 (2%) using non-rodent animal models (6 
rabbit, 3 monkey, 2 pig, 2 baboon, 3 macaque, 1 marmoset, 1 dog).  All papers within the VCI 
scope used rodents, with 28 (76%) of papers carried out in mice and 9 (24%) in rats.  
 
There was a sex bias in animal models employed, with the majority using males, irrespective of 
species (Figure 3B).  For stroke papers, 535 (84%) used males, 22 (3%) females, 28 (4%) both 
male and female and 51 (8%) sex unspecified.  Males were used in 23 (62%) VCI studies, 
females in 1 (3%), both male and female in 6 (16%) and 7 papers (19%) did not specify sex.  In 
both stroke and VCI studies, when females were used it was most commonly in conjunction with 
male animals.  Only 22 stroke and 1 VCI paper used solely female animals. 
 
There were 10 distinct disease models used in stroke and 11 in VCI studies (Supplementary 
Table II).  Ischemic stroke was more commonly studied with 559 (88%) papers, while 
hemorrhagic stroke was investigated in 84 (13%) of papers.  Transient middle cerebral artery 
occlusion (tMCAO) was the most common stroke model, used in 342 (54%) papers with 
permanent MCAO in 109 (17%) papers.  Other models of ischemic stroke included thrombotic 
stroke, endothelin-1 induced stroke, hypoxia-ischemia and global ischemia.  Hemorrhagic 
stroke papers used procedures directed to create an intracerebral, subarachnoid or 
intraventricular bleed (Supplementary Table II). 
 
In VCI research, permanent global hypoperfusion was the most common model, utilized in 11 
(30%) papers.  Alzheimer’s disease (AD) models, such as amyloid precursor protein (APP) 
mutations, were the second most common model, with AD pathology being used on its own or 
in conjunction with other co-morbidities such as hypertension, dyslipidemia and stroke.  Other 
models included post-stroke (tMCAO) dementia; microinfarcts, hypertension or dyslipidemia-
induced vascular dementia and transforming growth factor-induced cerebral fibrosis 
(Supplementary Table II).  
 
Variation in functional outcome measures used in stroke studies 
There were 74 different functional outcome measures recorded across stroke papers 
(Supplementary Table III).  Of these, 42 described functional tasks, where a specific behavior 
was monitored and recorded, and 32 described various neurological deficit scores (NDS).  
Examining only the top 10 outcome measures used in stroke studies, NDS were the most 
frequently named functional measure (Figure 4A), used in 471 (74%) papers with several 
variations used (Supplementary Table IV).  The Bederson et al. (1986)15 NDS scale was the 
most commonly cited in 175 papers.  Modified versions of original scales were considered as 
separate measures where scale content, scoring or application differed from the primary 
description.  Ten different variations of scoring were found amongst those citing Bederson15; 
ranging from 0-3 to 0-20 (Supplementary Table V).  In 29 (6%) papers NDS scales were not 
referenced or the method was left unnamed.  Of the specific functional tests, Rotarod was the 
most commonly used in 94 (15%) papers (Figure 4A).  Rotarod, grid walk/foot fault, adhesive 
label removal, cylinder, and string/wire/swing tests were the five most frequently used 
sensorimotor assessments and together were present in 327 (51%) of studies.  
 
Considering functional outcome measures used according to the most commonly used stroke 
models, in papers using intraluminal filament to induce tMCAO or pMCAO the NDS (77%) and 
rotarod (17%) were most commonly used (Table 1).  For the endothelin-1 tMCAO model, the 
most commonly reported outcome measure was the skilled-reaching/staircase test and cylinder 
tests (both 41%) (Figure 5A).  In thrombotic stroke models, the preferred outcome measure 
reported was the NDS (56%) and adhesive removal test (26%) (Figure 5B). 
 
The median number of outcome measures used per trial was 1 (range 1-10; IQR:1).  Only 57 
(9%) stroke papers reported functional outcome measures as their primary endpoint.  The 
prevalence of reporting more than one outcome measure demonstrated the majority (344 
papers, 54%) used one (Figure 6A); this dropped to 159 papers, 25% for 2 measures and 
continued downwards with increasing number of measures (Figure 6A).  The top two most 
commonly employed measures, NDS and Rotarod, were shared across rodent models.  In the 
20 non-rodent studies, NDS were used as the only functional measure in all but one study.  
Within the 9 primate studies that applied NDS, there were 5 different original scales cited.  The 
six rabbit studies all applied a different NDS.  The two piglet stroke studies each employed a 
different version of the same NDS. 
 
Variation in functional outcome measures used in VCI studies 
There were 20 different types of assessments used (Supplementary Table VI), which were 
predominantly tasks involving memory (8 assessments) or motor coordination (8 assessments).  
Only 7 (19%) VCI studies reported functional outcome measures as their primary endpoint.  
Examining, the top 10 most commonly used outcome measures in VCI papers (Figure 4B), 
demonstrated the Morris Water Maze (MWM)16 was most commonly used, irrespective of 
species and was used in 22 (60%) papers (with one completing 2 trials, hence 23 trials).  Other 
commonly applied tasks were novel object recognition, T or Y radial maze, locomotor activity 
and NDS, found in 27 (73%) of studies (Figure 4B).  The median number of functional 
assessments used in VCI papers was 1 (range 1-11, IQR:1).  The prevalence of reporting more 
than one outcome measure demonstrated the majority (20 papers, 54%) used one (Figure 6B); 
this dropped to 10 papers, 27% for 2 measures and continued downwards with increasing 
number of measures (Figure 6B).   
 
Within papers using the MWM, there was notable heterogeneity within the methodology of the 
test (Table 2).  Some studies used a submerged platform (14 trials; 61%), whereas others a 
visible platform (4 trials; 17%) or a combination (5 trials; 22%).  There were also differences in 
external cues used to assist in finding the platform (56% used cues versus 44% no cues) and 
whether these cues were visual or olfactory/auditory.  There was a preference towards including 
a probe trial, where the platform is removed and the swimming latency is recorded to test 
retention memory, but this was inconsistent across all studies (78% and 22%, respectively).  
There was further variability in the number of acquisition days (between 0-10 days, IQR: 2.5) 
allowed before endpoint assessment; the number of trials performed per day (1-8 trials per day, 
IQR: 2); the timing of the probe trial (range 3-10 days, IQR: 1.25), and whether there were 
further trials after the probe trial (39% studies applying probe trials had post-probe trials, 61% 
did not).  
 
 
DISCUSSION  
The traditional paradigm for assessing efficacy in preclinical stroke and VCI trials has been a 
combination of neurological assessments with measurements of infarct volume.  Use of 
functional assessments as primary outcome or to complement other outcomes is increasingly 
recommended in both clinical and preclinical research.  In the present review, papers from 14 
journals from the past 11 years were investigated to describe the functional outcome measures 
used in preclinical trials of stroke and VCI.  Although functional assessments are mandated in 
clinical stroke trials, functional assessments were the primary outcome in only a minority of 
outcomes used in preclinical models.  The landscape may be changing, as there was an 
increase in papers reporting functional outcome measures over the time horizon of the study.  
Where functional outcomes were used there was substantial heterogeneity in the assessment 
and application of the assessment.  There was greater consistency in the sex and species of 
animal model, although a predominant focus on male animals is not in keeping with best 
practice.  
 
The observed increase in stroke papers reporting functional measures from 2010 onwards 
could be partly attributed to the publication of the revised STAIR guidelines in 20094.  These 
guidelines emphasize not only the importance of using functional outcome measures, but also 
problems inherent in using multiple outcome measures.  Indeed, a recent editorial by Zerna et. 
al.17 highlighted the choice of endpoint remains challenging in the preclinical stroke field.  While 
not as many papers were identified for VCI preclinical studies, those reporting outcome 
measures increased temporally across the 11 year period, which may reflect a shift in research 
focus towards dementia18. 
 
The predominant (98%) or exclusive use of rodent models in stroke and VCI studies, 
respectively, is consistent with other animal disease models.  Their use is favored for several 
reasons - maintenance costs are low, use is preferred ethically, availability of transgenic strains 
and the vascular anatomy is similar to human (reviewed in 19, 20).  Considerations for stroke/VCI 
studies include that rodents have less white matter than humans since they have lissencephalic 
brains.  STAIR4 recommend that once efficacy is established in a rodent model that larger 
animal models are studied prior to clinical translation.  Another key consideration in the 
translation pipeline is the inclusion of disease-relevant comorbidities and risk factors, such as 
hypertension and aging for stroke/VCI studies, highlighted in STAIR and other recent 
guidelines4, 21.  Presence of existing comorbidities across the studies described herein was not 
included in the inclusion/exclusion criteria as based on previous studies, consideration of such 
co-morbidities occurred in a minority (3%) of reports of therapeutic interventions in stroke22. 
 
Even though women are more likely affected by post stroke disability23, males are more often 
used in preclinical research and within those studies included in this review, 89% of stroke and 
68% of VCI studies used male animals.  The focus on males most likely limits cohort sizes and 
variability through removal of the effect of the estrous cycle in females.  However, the 
importance of considering sex as a biological variable has been discussed extensively4, 24, 25.  
This followed the publication of the National Institute of Health guidance highlighting that sex 
differences should be factored into experimental design26.  Sex has significant effects on many 
biological processes (reviewed in 27) and certain interventions, such an inhibition or knockout of 
neuronal nitric oxide synthase (nNOS) or poly-ADP ribose polymerase-1 (PARP-1), have shown 
protection in male animals subjected to experimental stroke and exacerbation of injury in 
females28.  Within the studies included here, when females were used this was most commonly 
in conjunction with male animals.  The recent publication of the ‘Sex and Gender Equity in 
Research’ guidelines29 combined with grant review considerations may lead to a shift in the 
inclusion of both sexes in experimental stroke and VCI studies in coming years. 
 
Eleven models of both stroke and VCI were described.  Most stroke studies used an ischemic 
model with tMCAO being the most widely employed.  For VCI, the permanent global 
hypoperfusion model was the most commonly used.  The choice of experimental stroke model 
used will be tailored to the therapeutic intervention being trialed and considerations such as 
whether reperfusion should occur or the size and location of the lesion required.  Indeed, 
differences in the choice of preferred outcome measure was evident comparing across stroke 
models.  The relative merits and limitations of each model are reviewed elsewhere19, 20, 30, 31.  
Similarly, for VCI studies, the biological question being addressed will determine the most 
appropriate model to use.  Models that produce lesions in distinct locations require outcome 
assessments that are relevant to the affected brain region.  For example, the use of the skilled 
reach/staircase test or cylinder test when the endothelin-1 stroke model was used reflects the 
cortical lesion produced.  However, an exclusive focus on impairment measures specific to the 
lesion is a reductionist approach and potentially fails to capture the biological variability in 
response; the remote consequences of targeted lesions and the limited correlation between 
neuroanatomy and function.  Global assessments of functional outcome should be relevant to 
any stroke lesion and could form part of a core set of outcomes complemented by other specific 
tests. 
 
There were 74 different functional measures used in stroke preclinical studies.  The most 
frequently used was NDS, although within this group there was marked heterogeneity in NDS 
used and the application of the test.  These scales (or scores) generally reflect overall condition, 
assessing reflexes, simple motor function and balance (reviewed in 32).  They are often 
preferred as they can be performed soon after experimental stroke and generally do not require 
specialized equipment.  However, NDS are not a distinct behavioral measure per se, rather 
NDS are normally composed of various components that quantify the global stroke related 
impairment over time with inherent limitations due to subjectivity of scores.  The most commonly 
used NDS, Bederson15, gives a total score of 0-3 in the original scale.  This limited range of 
possible scores lacks sensitivity for assessing change with subsequent effects on sample size 
requirements and has led to a range of modified Bederson scales with a greater number of 
components. 
 
A further challenge with the NDS was distinguishing between the methodologies used.  From 
the NDS or battery tests described, most were named by referencing the original authors who 
first developed the tools, or by referencing authors who had previously used the tools.  The 
referencing was further complicated by publication of subsequent and different modified 
versions of the originals, each with their own authors further modifying the scale.  
Comprehensive descriptions of the methodology of each assessment were infrequent and the 
original method was often left unclear.  There were also multiple papers where methods were 
not clarified with appropriate citations or descriptions.  Without clear methodology, interpreting 
between NDS becomes complex.  Poor reporting makes it difficult to replicate experiments in 
independent cohorts and ultimately limits the validity of the research and  potential to use the 
data for comparative or pooled analyses such as systematic reviews and meta-analyses33.  
Within the clinical arena, there have been numerous efforts leading to a consensus in preferred 
outcome measures in clinical trials34 and our findings suggest that this could be applied in 
preclinical research. 
 
In VCI studies, 20 different functional assessments were recorded.  While common standards 
exist for identifying and describing cognitive impairment clinically, these recommendations do 
not extend to preclinical VCI study reporting35.  Nevertheless, assessing cognitive impairment is 
crucial to validate the disease model and to further assess the effects of interventions.  The 
MWM was the most commonly used outcome measure across all studies in mice or rats.  
However, there was clearly marked inconsistencies across the methodology used in these 
studies which would, again, make pooled analyses difficult.  Indeed, this is consistent with a 
recent systematic review of AD mouse models where substantial variation in methodology in the 
use of the MWM was found with 57 studies using the probe phase using 59 different 
approaches36.  The substantial variations in characteristics of the MWM set-up alter which 
aspects of memory retention and learning are being assessed37.  In stroke studies, use of a pre-
determined performance criterion within assessment of the MWM has been recommended in 
order to avoid potential misinterpretation of data38.  Furthermore, it has been shown that rats 
outperform mice when using the MWM as an assessment measure39.  Many of the assessments 
used in VCI models were first proposed for animal models of other dementia pathologies e.g. 
AD.  Assessments that predominantly describe memory may miss important impairments in 
other domains commonly seen in VCI, for example the complex constructs of executive 
function.  Recently, models used in VCI preclinical trials have been under review40, but for more 
effective clinical translation, the appropriateness of functional outcome measures for each 
model should also be evaluated.  
 
There were strengths and limitations to the search conducted.  The large and increasing stroke 
literature precluded a comprehensive review of outcomes across all published preclinical stroke 
and VCI trials.  The analysis was limited to journals with a large readership across the 
disciplines of clinical and translational neurovascular research over an 11-year period.  
Consequently, the sampling frame is potentially biased.  Important studies describing VCI could 
be published in a variety of journals.  Our focus on cerebrovascular disease and non-inclusion 
of dementia specific titles may have affected the yield of VCI papers.  However, the intention 
was to describe the outcome measures used in journals with the greatest scientific impact, 
rather than across the complete stroke and VCI literature.  Our focus was predominantly on 
measures of sensorimotor or cognitive outcome.  These may not be the only “functional” 
outcomes of relevance.  Recent priority setting exercises have suggested that emotional and 
mood symptoms are the issues of greatest importance to stroke survivors41.  Although not 
comprehensive, the search strategy was systematic.  A systematic approach was necessary for 
describing the assessment methods employed.  As numerous papers only referred to the 
assessment method used, the stated functional outcome tool was cross-referenced, sometimes 
across several papers, to obtain the original description of the assessment method used.  The 
intention was purely to describe current outcome assessment methods and no attempt was 
made to compare the strengths and weaknesses of different instruments or to assess the 
methodological approaches described in the trials.  There have been recent efforts to evaluate 
the validity of various assessments in certain models of stroke42, 43, and there would be value in 
expanding this evaluation to include the many stroke and VCI preclinical models described in 
the literature. 
 
The need to determine neurological deficit and function as an outcome measure within stroke 
and VCI studies is imperative for potential clinical translation.  The marked heterogeneity 
described is perhaps unsurprising as there are no agreed pre-set guidelines for functional 
assessment measures preclinically.  Consistency across studies will facilitate easier between 
study comparisons and pooling of preclinical data.  In clinical trials, work by groups such as 
EQUATOR (Enhancing the Quality and Transparency of Health Research) has raised standards 
in reporting of research methods.  The work of collectives such as the CAMARADES group is 
trying to replicate this success in preclinical models.  It is encouraging to see emerging 
guidance around preferred assessments, albeit this is limited to a specific aspect of 
cerebrovascular research.  For example, the Stroke Recovery and Rehabilitation Roundtable 
have recently produced guidance for behavioural outcome measures44, 45.  Considerable efforts 
and advances have been made in improving design, conduct and analysis in stroke research21, 
45, 46, with improvements in terms of rigor and reduced bias reflecting the changes 
implemented47.  Indeed, in comparison to other areas, preclinical stroke research in particular, is 
performing well against targets to enhance reproducibility and promote translation48.   
 
In this context of increasing standardization of methods in clinical research, one possible 
interpretation of our results is that the preclinical stroke research community should move 
towards a core set of preferred functional outcomes measures.  While few would argue against 
improving rigor and transparent reporting, restricting the choice of outcome assessments 
available may not suit translational and discovery science.  The nature of preclinical research is 
often more exploratory compared to the confirmatory nature of clinical trials and indeed, over-
standardization of laboratory studies may have the opposite intended effect and result in poor 
reproducibility49.  For hypothesis generating pre-clinical studies it is arguable whether functional 
assessment adds value to other surrogate outcomes such as neuroimaging.  Perhaps a more 
suitable suggestion would be that for larger scale preclinical studies, researchers use at least 
one functional outcome measure with standardized approaches to assessment and scoring in 
addition to any assessments specific to the scientific question of interest.  
 
In conclusion, we have demonstrated that functional outcome measures are increasingly being 
used in preclinical cerebrovascular research but when they are employed, substantial 
heterogeneity in the measures chosen and their application exists.  This inconsistency in 
conduct and reporting limits the potential for comparative or meta-analyses.  The clinical 
research community have developed preferred outcomes but strict control of the tests available 
to researchers may not always be suitable in preclinical work.  There are other avenues 
available, including standardized operating procedures, standardized scoring criteria, guidance 
on reporting outcome assessments and many others.  The preclinical research community must 
now work together to improve consistency and transparency and we would welcome any 
initiatives that look to develop these resources. 
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Figure 1: Strategy implemented in the focused literature search.  Papers were selected on 
the basis of set inclusion/exclusion criteria and after further comprehensive review, papers that 
had no reported functional outcome measures as their primary or secondary endpoint were 
excluded from the final analysis.  This yielded 636 papers for stroke and 37 for vascular 
cognitive impairment (VCI). 
 
Figure 2: Number of papers published each year with functional assessments.  The 
number of preclinical stroke (A) or VCI (B) papers reporting functional assessments over the 11 
years of the review period.  The number of papers per year in stroke and VCI, respectively 
were: 2005: 29,1; 2006: 30, 1; 2007: 32, 2; 2008: 37, 1; 2009: 38, 5; 2010: 33, 2; 2011: 97, 3; 
2012: 75, 3; 2013: 101, 5; 2014: 82, 2; 2015: 82, 12.  A significant increase in stroke papers 
describing functional outcome assessments was observed after 2010 (unpaired t-test; 
***p<0.0001 comparing articles from 2000-2010 vs. articles 2011-2015, inclusive).  Data 
generated from 14 specified peer reviewed journals (Supplementary Table I). 
 
Figure 3: The prevalence of species and sex of animals used in stroke and VCI papers. 
(A) The percentage of papers using each species in stroke and VCI studies.  (B) The 
percentage of papers using each sex across stroke and VCI studies.  Percentage was 
calculated as portion of total amount of papers included in the final analysis (n=636 and n=37, 
respectively). 
 
Figure 4: Top 10 functional assessments used in preclinical stroke or VCI papers.  Top 10 
functional assessments in (A) stroke papers (n=636) and (B) VCI papers (n=37) included in the 
final analysis.  Percentage was calculated as a portion of all papers included. 
 
Figure 5: Prevalence of outcome measures used in papers according to stroke model.  
The preferred functional outcome measure used in papers using (A) endothelin-1 or (B) the 
thrombotic model to induce experimental stroke was determined.  Percentage was calculated as 
a portion of all papers included (A: n=22; B n=57). 
 
Figure 6: Prevalence of the number of different outcome measures reported in preclinical 
stroke or VCI papers.  The number of preclinical stroke papers using one or more functional 
outcome measures was determined for (A) stroke and (B) VCI papers.  These represented for 
increasing number of outcome measures employed: (A) 1=344 papers (54%), 2=159 (25%), 
3=81 (13%), 4=34 (5%), 5=7 (1%), 6=6 (1%), 7=1 (0.2%), 8=0 (0%), 9=1 (0.2%), 10=4 (1%) and 
(B) 1=20 papers (54%), 2=10 (27%), 3=4 (13=11%), 4=1 (3%), 5=0 (0%), 6=0 (0%), 7=0 (0%), 
8=1 (3%), 9=0 (0%), 10=0 (0) 11=1 (3%).  Percentage was calculated as a portion of all papers 
included. 
  
Table 1: Prevalence of outcome measures used in papers using the intraluminal filament 
tMCAO and pMCAO stroke models.  The preferred functional outcome measure used in 
papers using the intraluminal filament to induce tMCAO or pMCAO was determined.  
Percentage was calculated as a portion of all papers included (n=305 and n=104, tMCAO and 
pMCAO respectively) 
 
Functional Assessment tMCAO, n(%) pMCAO, n(%) 
Neurological deficit score 246 (81) 48 (46) 
Rotarod 53 (17) 22 (21) 
String / Wire / Grip / Swing test 31 (10) 8 (8) 
Adhesive removal test 26 (9) 16 (15) 
Beam / Rope test 22 (7) 1 (1) 
Grid walk / Foot fault 22 (7) 13 (13) 
Cylinder test 19 (6) 9 (9) 
Locomotor activity 16 (5) 9 (9) 
Corner turn test 14 (5) 8 (8) 
Limb placing test 13 (4) 12 (12) 
Morris water maze 12 (4) 11 (11) 
Tail suspension / Body swing 8 (3) 6 (6) 
Side-walking / Circling / Rotation 5 (2) 2 (2) 
Postural reflex 4 (1) 3 (3) 
Gait analysis 4 (1) 2 (2) 
T or Y or radial arm maze 3 (1) 1 (1) 
Barnes maze 3 (1) 1 (1) 
Elevated plus or O maze 2 (1) NA 
Skilled-reaching / Staircase task 2 (1) 8 (8) 
Ladder test 2 (1) 6 (6) 
Novel object recognition 2 (1) NA 
Whisker / Tactile 2 (1) 1 (1) 
Passive avoidance 1 (0.3) 2 (2) 
Fear conditioning 1 (0.3) 1 (1) 
Parallel bar crossing 1 (0.3) 1 (1) 
Inclined plane test 1 (0.3) NA 
Right forelimb resting motor threshold 1 (0.3) NA 
Drinking Efficiency 1 (0.3) NA 
Social novel odour recognition task 1 (0.3) NA 
Hindlimb retraction 1 (0.3) NA 
Rotameter task 1 (0.3) NA 
Forced swim test NA 1 (1) 
Stress test (max speed) NA 1 (1) 
Step test NA 1 (1) 
 
 
  
Table 2: Variation in the characteristics of Morris Water Maze (MWM).  Differences in 
characteristics of MWM used in the papers shown as differences in set-up, presence and type 
of cues as well as with the presence of a probe trial, where platform was removed from the pool.  
Percentages were calculated as total amount of papers using MWM (n=23). 
 
Variation used Papers using MWM, n (%) 
Platform type (n=23)  
Submerged platform 14 (70) 
Both types of platform 5 (22) 
Visible platform 4 (17) 
Cue type (n=23)  
Visual cues 12 (52) 
No cues 10 (44) 
Olfactory/Auditory/Spatial 1 (4) 
Presence of probe trial (n=23)  
Probe trial 18 (78) 
No probe trial 5 (22) 
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